激情综合啪啪6月丁香,久久久久国产精品91福利,99精品日韩欧美在线观看,91成人午夜福利在线观看国产

技術(shù)中心

干擾埃博拉病毒繁殖突破性進(jìn)展

2010年05月31日 08:56:00人氣:1704來源:上海勁馬實(shí)驗(yàn)設(shè)備有限公司

資料類型文件資料大小
下載次數(shù)72資料圖片 【點(diǎn)擊查看】
上 傳 人上海勁馬生物科技有限公司需要積分0
關(guān) 鍵 詞干擾埃博拉病毒繁殖突破性進(jìn)展
暫無上傳相關(guān)文件
【資料簡(jiǎn)介】

美國(guó)波士頓大學(xué)醫(yī)學(xué)院“全國(guó)潛在傳染病實(shí)驗(yàn)室”專家托馬斯·蓋斯伯特領(lǐng)導(dǎo)一個(gè)團(tuán)隊(duì),選取兩組恒河獼猴應(yīng)用這種試驗(yàn)性藥物。

美國(guó)研究者利用微粒狀基因物質(zhì)干擾埃博拉病毒繁殖的研究取得突破性進(jìn)展。實(shí)驗(yàn)室研究表明,感染埃博拉病毒的恒河獼猴接受一種試驗(yàn)性藥物治療后死亡率降低。

研究人員介紹,這種藥物含有的小型干擾核糖核酸會(huì)抑制酶的誘生,從而達(dá)到干擾病毒繁殖的目的。

研究人員先為*組中3只獼猴注射可致命劑量的埃博拉病毒亞型“埃博拉-扎伊爾”,隨后數(shù)天連續(xù)為這些獼猴注射4劑試驗(yàn)性藥物,結(jié)果其中一只獼猴死亡。

第二組4只獼猴注射同等劑量這種病毒亞型后,連續(xù)接受7劑試驗(yàn)性藥物治療,結(jié)果全部存活。

兩組實(shí)驗(yàn)猴中均有一只獼猴染病后沒有接受試驗(yàn)性藥物治療,zui終死亡。

蓋斯伯特說,這是研究人員制出一種能令非人類靈長(zhǎng)類動(dòng)物感染埃博拉病毒后存活的藥物,具有突破性意義。

“我們認(rèn)為,研究為將這種試驗(yàn)性處方發(fā)展為(批量)制劑、用于埃博拉病例治療提供了論證,無論是在實(shí)驗(yàn)室病毒外泄還是這種疾病暴發(fā)的情形下。”

埃博拉病毒可導(dǎo)致埃博拉病毒出血熱,患者可出現(xiàn)發(fā)熱、惡心、嘔吐、腹瀉、全身酸痛、體內(nèi)外出血等癥狀,致死率可達(dá)90%。

世界衛(wèi)生組織數(shù)據(jù)顯示,自1976年發(fā)現(xiàn)感染埃博拉病毒病例以來,累計(jì)報(bào)告大約1850例這類病例,其中約1200例死亡。

上海勁馬生物()推薦原文出處:

The Lancet Doi:10.1016/S0140-6736(10)60357-1

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
Prof Thomas W Geisbert PhD a b c , Amy CH Lee MSc e ?, Marjorie Robbins PhD e ?, Joan B Geisbert a, Anna N Honko PhD d, Vandana Sood MSc e, Joshua C Johnson BSc d, Susan de Jong PhD e, Iran Tavakoli BSc e, Adam Judge PhD e, Lisa E Hensley PhD d, Ian MacLachlan PhD e

Background

We previously showed that small interfering RNAs (siRNAs) targeting the Zaire Ebola virus (ZEBOV) RNA polymerase L protein formulated in stable nucleic acid-lipid particles (SNALPs) compley protected guineapigs when administered shortly after a lethal ZEBOV challenge. Although rodent models of ZEBOV infection are useful for screening prospective countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models. We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever.

Methods

A combination of modified siRNAs targeting the ZEBOV L polymerase (EK-1 mod), viral protein (VP) 24 (VP24-1160 mod), and VP35 (VP35-855 mod) were formulated in SNALPs. A group of macaques (n=3) was given these pooled anti-ZEBOV siRNAs (2 mg/kg per dose, bolus intravenous infusion) after 30 min, and on days 1, 3, and 5 after challenge with ZEBOV. A second group of macaques (n=4) was given the pooled anti-ZEBOV siRNAs after 30 min, and on days 1, 2, 3, 4, 5, and 6 after challenge with ZEBOV.

Findings

Two (66%) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs were protected from lethal ZEBOV infection, whereas all macaques given seven postexposure treatments were protected. The treatment regimen in the second study was well tolerated with minor changes in liver enzymes that might have been related to viral infection.

Interpretation

This complete postexposure protection against ZEBOV in non-human primates provides a model for the treatment of ZEBOV-induced haemorrhagic fever. These data show the potential of RNA interference as an effective postexposure treatment strategy for people infected with Ebola virus, and suggest that this strategy might also be useful for treatment of other emerging viral infections.

Funding
Defense Threat Reduction Agency.

上海勁馬實(shí)驗(yàn)設(shè)備有限公司作者

上一篇:探討運(yùn)動(dòng)粘度測(cè)定儀的功能

下一篇:了解誤碼測(cè)試儀的功能


我要投稿
  • 投稿請(qǐng)發(fā)送郵件至:(郵件標(biāo)題請(qǐng)備注“投稿”)hbzhan@vip.qq.com
  • 聯(lián)系電話0571-87759680
環(huán)保行業(yè)“互聯(lián)網(wǎng)+”服務(wù)平臺(tái)
環(huán)保在線APP

功能豐富 實(shí)時(shí)交流

環(huán)保在線小程序

訂閱獲取更多服務(wù)

微信公眾號(hào)

關(guān)注我們

抖音

環(huán)保在線網(wǎng)

抖音號(hào):hbzhan

打開抖音 搜索頁掃一掃

視頻號(hào)

環(huán)保在線

公眾號(hào):環(huán)保在線

打開微信掃碼關(guān)注視頻號(hào)

快手

環(huán)保在線

快手ID:2537047074

打開快手 掃一掃關(guān)注
意見反饋